跳至主要内容
临床试验/CTRI/2020/03/023900
CTRI/2020/03/023900招募中未知

A randomized controlled trial of therapeutic monitoring-based dosing strategy versus standard dosing strategy of sunitinib in metastatic renal cell carcinoma

Advanced Cancer for Treatment Research and Education0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1 Adults of age 18 years and above
  • 2 Histologically or cytologically proven mRCC
  • 3 Chemo-naïve patients eligible for single agent sunitinib
  • 4 Patient willing to give written informed consent

排除标准

  • 1 Patient with malignancies other than mRCC
  • 2 Patient received one or more dose of sunitinib previously
  • 3 Patients with active HIV infection and serology positive for HBV,HCV ,HAV
  • 4 History of severe liver disease or other uncontrollable medical condition
  • 5.Patients on concomitant drugs which are CYP3A4 inducers or inhibitors

研究者

发起方
Advanced Cancer for Treatment Research and Education

相似试验